Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy

Gynecologic Oncology

Volumn 104, Issue 1, 2007, Pages 104-108

  Petit, Thierry ^a,b   Velten, Michel ^b   d'Hombres, Anne ^c   Marchal, Christian ^d   Montbarbon, Xavier ^a   Mornex, Françoise ^c   Quetin, Philippe ^b   Gérard, Jean Pierre ^e   Romestaing, Pascale ^c   Carrie, Christian ^a  

^a CENTRE LÉON BÉRARD   (France)

^b CLCC Paul Strauss   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d Alexis Vautrin Cancer Center   (France)

^e CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Long term follow up; Ovarian carcinoma; Radiotherapy; Stage III

Indexed keywords

ALTRETAMINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; VINCRISTINE;

ACUTE TOXICITY; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; ENTERITIS; FATALITY; FEMALE; FOLLOW UP; FRANCE; HUMAN; INTESTINE OBSTRUCTION; INTESTINE SURGERY; LAPAROTOMY; LINEAR ACCELERATOR; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVARY ADENOCARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION ENTEROPATHY; RADIATION SICKNESS; SECOND LOOK SURGERY;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LAPAROTOMY; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEOPLASMS, SECOND PRIMARY; OVARIAN NEOPLASMS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SECOND-LOOK SURGERY; TREATMENT OUTCOME;

EID: 33846002379     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.07.034     Document Type: Article

References (20)

1. Ozols R.F., Rubin S.C., Thomas G.M., and Robboy S.J. Epithelial ovarian cancer. In: Hoskins W.J., Perez C.A., Young R.C., Barakat R., Markman M., and Randall M. (Eds). Principles and practice of gynecologic oncology (2005), Lippincott Williams and Wilkins 895-988
2. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
3. Markman M., Liu P.Y., Wilczynski S., Monk B., Copeland L.J., Alvarez R.D., et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 21 (2003) 2460-2465
4. Varia M.A., Stehman F.B., Bundy B.N., Benda J.A., Clarke-Pearson D.L., Alvarez R.D., et al. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21 (2003) 2849-2855
5. Dufour P., Bergerat J.P., Barats J.C., Giron C., Duclos B., Dellenbach P., et al. Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer 73 (1994) 1865-1869
6. Donato M.L., Aleman A., Champlin R.E., Saliba R.M., Wharton J.T., Burke T.W., et al. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant. 33 (2004) 1219-1224
7. MacGibbon A., Bucci J., MacLeod C., Solomon J., Dalrymple C., Firth I., et al. Whole abdominal radiotherapy following second-look laparotomy for ovarian cancer. Gynecol. Oncol. 75 (1999) 62-67
8. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
9. Dinniwell R., Lock M., Pintilie M., Fyles A., Laframboise S., Depetrillo D., et al. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer. Int. J. Radiat. Oncol. Biol. Phys. 62 (2005) 104-110
10. Rahaman J., Dottino P., Jennings T.S., Holland J., and Cohen C.J. The second-look operation improves survival in suboptimally debulked stage III ovarian cancer patients. Int. J. Gynecol. Cancer 15 (2005) 19-25
11. Rose P.G., Nerenstone S., Brady M.F., Clarke-Pearson D., Olt G., Rubin S.C., et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N. Engl. J. Med. 351 (2004) 2489-2497
12. Thomas G.M. Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer?. Gynecol. Oncol. 51 (1993) 97-103
13. Bruzzone M., Repetto L., Chiara S., Campora E., Conte P.F., Orsatti M., et al. Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. Gynecol. Oncol. 38 (1990) 392-395
14. Lawton F., Luesley D., Blackledge G., Hilton C., Kelly K., Latief T., et al. A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West Midlands Ovarian Cancer Group Trial II. Clin. Oncol. 2 (1990) 4-9
15. Lambert H.E., Rustin G.J.S., Gregory W.M., and Nelstrop A.E. A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group Study. J. Clin. Oncol. 11 (1993) 440
16. Pickel H., Lahousen M., Petru E., Stettner H., Hackl A., Kapp K., et al. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Gynecol. Oncol. 72 (1999) 215-219
17. Sorbe B., and Swedish-Norgewian Ovarian Cancer Study Group. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int. J. Gynecol. Cancer 13 (2003) 278-286
18. Piccart M.J., Floquet A., Scarfone G., Willemse P.H., Emerich J., Vergote I., et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int. J. Gynecol. Cancer 13 (2003) 196-203
19. Markman M, Liu P, Wilczynski S, Monk B, Copeland L, Alberts D. Survival of ovarian cancer patients treated on SWOG9701/GOG178: 12 versus 3 cycles of monthly single-agent paclitaxel following attainment of a clinically-defined complete response to platinum. 2006 ASCO Annual Meeting Proceedings, abs 5005.
20. Curé C., Battista H., Guastalla J.P., Fabbro M., Tubiana-Mathieu N., Bourgeois H., et al. Phase III randomized trial of high-dose chemotherapy and peripheral blood stem cell support as consolidation in patients with advanced ovarian cancer: 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. Proc. Am. Soc. Clin. Oncol. 204a (2004) [abs 5006]